Figure 4

Proposed treatment strategy for recurrent disease after radical prostatectomy. The OR that patients with three favorable factors will experience BCR after SRT monotherapy is 0.084 (95% CI 0.01-0.72). Patients showing biochemical recurrence after a decline to PSA < 0.2 ng/mL and those showing nonresponse to SRT can be distinguished by the status of the surgical margin and PSAV. The former may benefit from the combination of SRT and short course of ADT, while the latter may not receive benefit from SRT.